23248
Specialized clinical information about coronavirus COVID-19
The situation is rapidly evolving, and information is being constantly updated. Last updated
View FAQs about COVID-19 and people living with HIV
View FAQsUpdated! General Information about COVID-19
UNAIDS
Coronavirus Innovation Map
Global map of innovative solutions created in response to Covid-19.
Johns Hopkins University
Coronavirus (COVID-19) world map
ECDC
Situation update for the EU/EEA and the UK
USA
Updated! HIV and COVID-19
Updated! WHO
UNAIDS
Other
EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) and SARS-CoV-2 vaccine advice for adults living with HIV
Updated! COVID-19 (medical information)
Updated! WHO
Drug Interaction COVID-19
Drug interactions with experimental COVID-19 therapies.
Guidelines for treatment of COVID-19
Inpatient guidance for treatment of COVID-19 in adults and children (University of Michigan,
USA)
Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19
(Италия, Ломбардия)
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)
(Released by National Health Commission & State Administration of Traditional Chinese Medicine)
Clinical trials and scientific articles of COVID-19
COVID-19 - Resource Centres of scientific journals
General
Surface Stability
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to
days in
aerosols and on surfaces. The scientists found that severe acute respiratory syndrome
coronavirus 2
(SARS-CoV-2) was detectable in aerosols for up to three hours, up to four hours on copper,
up to 24
hours on cardboard and up to two to three days on plastic and stainless steel.
Remdesivir
Vaccine
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Vulvar Aphthous Ulcers in Perimenarchal Adolescents after COVID-19 Vaccination: A Multicenter Case Series
“Vaccine-Induced Covid-19 Mimicry” Syndrome:
Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (Preprints)
A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)
Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine
Increased efficacy with longer inter-dose interval. Protection of over 70% starting after a first dose. First indication of reduction in disease transmission of up to 67%
Updated! Corticosteroid dexamethasone
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
View FAQs about COVID-19 and people living with HIV
View FAQsIf you have questions or comments about HIV and COVID-19, let us know [email protected]